Related Experiment Videos
Safety and efficacy of netilmicin in neonates with serious systemic infections
Insights
Netilmicin effectively treated serious infections in hospitalized neonates. The antibiotic demonstrated high efficacy, resolving symptoms in 24 of 25 infants with minimal adverse effects.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Neonates with serious symptomatic infections require effective and safe antimicrobial therapy.
- Aminoglycosides are commonly used for serious bacterial infections, but safety profiles in neonates are crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of netilmicin in treating serious symptomatic infections in hospitalized neonates.
- To assess the microbiological eradication rates of causative organisms following netilmicin treatment.
Main Methods:
- A prospective study involving 25 hospitalized neonates with two or more serious symptomatic infections.
- Intramuscular administration of netilmicin at 1.5 or 3.0 mg/kg twice daily for 7 to 13 days.
- Clinical assessment of infection resolution and microbiological analysis of causative organisms before and after treatment.
Main Results:
- Complete resolution of infection signs and symptoms was observed in 24 out of 25 neonates (96%).
- Marked improvement was noted in the remaining patient.
- Netilmicin therapy led to the complete elimination of 31 out of 35 isolated causative organisms (88.6%) and significant reduction in 4 others.
- One neonate experienced a slight, possibly therapy-related increase in serum creatinine and a mild, doubtfully related rash; no other adverse reactions were reported.
Conclusions:
- Netilmicin is a highly effective antibiotic for treating serious symptomatic infections in neonates.
- The safety profile of netilmicin in this neonatal population appears favorable, with minimal adverse events observed.
- Netilmicin demonstrates significant microbiological eradication capabilities against common neonatal pathogens.
Abstract:
Twenty-five hospitalized neonates, each with two or more serious symptomatic infections, were given netilmicin by intramuscular injection. The antibiotic was administered usually at 1.5 or 3.0 mg/kg twice a day (q 12 hr) for 7 to 13 days. At the end of therapy the signs and symptoms of infection were completely resolved in twenty-four of the twenty-five patients and markedly improved in the remaining one. Thirty-five causative organisms were isolated from 30 of the 59 infection sites; after netilmicin therapy 31 causative organisms were completely eliminated and 4 were markedly reduced in number. One of the babies had a slight increase in serum creatinine level, possibly related to therapy, and a mild transient rash which was doubtfully related to netilmicin. None of the other neonates had adverse reactions.